Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.

@article{McLellan2011DesignAC,
  title={Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.},
  author={Jason S McLellan and Bruno E. Correia and Man Chen and Yongping Yang and Barney S. Graham and William R. Schief and Peter D. Kwong},
  journal={Journal of molecular biology},
  year={2011},
  volume={409 5},
  pages={
          853-66
        }
}
Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, but an effective vaccine has not yet been developed. An ideal vaccine would elicit protective antibodies while avoiding virus-specific T-cell responses, which have been implicated in vaccine-enhanced disease with previous RSV vaccines. We propose that heterologous proteins designed to present RSV-neutralizing antibody epitopes and to elicit cognate antibodies have the potential to fulfill these… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Emerging Vaccine Technologies

VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Elicitation of structure-specific antibodies by epitope scaffolds.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2010
VIEW 4 EXCERPTS

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

B. S. Graham
  • Immunol. Rev
  • 2011

Computational design of epitope - scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

G. Ofek, F. J. Guenaga, +4 authors P. D. Kwong
  • Structure
  • 2010